CRGX — CARGO Therapeutics Income Statement
0.000.00%
HealthcareMid Cap
- $725.76m
- $349.84m
Annual income statement for CARGO Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Unusual Expense / Income | |||
Total Operating Expenses | 5.98 | 34.8 | 99 |
Operating Profit | -5.98 | -34.8 | -99 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -5.85 | -41 | -98.1 |
Net Income After Taxes | -5.85 | -41 | -98.1 |
Net Income Before Extraordinary Items | |||
Net Income | -5.85 | -41 | -98.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -5.85 | -41 | -98.1 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.151 | -1.06 | -2.33 |
Dividends per Share |